Milestone Pharmaceuticals Inc. (MIST)
Nasdaq: MIST · Pharmaceutical Preparations · Montreal, QC · filing with the SEC since 2007
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Report filed | Mar 20, 2026 | Mar 13, 2025 | Mar 21, 2024 | Mar 29, 2023 | Mar 24, 2022 | Mar 29, 2021 | Mar 6, 2020 | · |
| Research and development | 18,108 | 14,357 | 31,052 | 39,829 | 38,671 | 34,488 | 41,985 | 16,849 |
| General and administrative | 17,274 | 16,742 | 15,932 | 15,718 | 12,399 | 10,285 | 7,004 | 3,052 |
| Operating income | -62,140 | -42,102 | -61,098 | -59,642 | -43,073 | -50,710 | -57,881 | -23,822 |
| Interest expense | 3,838 | 3,581 | 2,554 | · | · | · | · | · |
| Interest and investment income | 2,920 | 4,164 | 3,967 | · | 220 | 726 | 2,596 | 711 |
| Interest income (expense), net | · | · | 3,967 | 1,254 | 220 | · | · | · |
| Income before income taxes | -63,058 | -41,519 | -59,685 | -58,388 | -42,853 | -49,984 | -55,285 | -23,111 |
| Income tax expense | · | · | · | · | · | -17 | -56 | 74 |
| Net income including non-controlling interests | -63,058 | -41,519 | -59,685 | -58,388 | -42,853 | -49,967 | -55,229 | -23,185 |
| Net income | -63,058 | -41,519 | -59,685 | -58,388 | -42,853 | -49,967 | -55,229 | -23,185 |
| Earnings per share, basic | -0.75 | -0.67 | -1.39 | -1.38 | -1.02 | -1.70 | · | · |
| Earnings per share, diluted | -0.75 | -0.67 | -1.39 | -1.38 | -1.02 | -1.70 | · | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -1.70 | -3.50r | 72.63 |
| Weighted average shares, basic and diluted | · | · | · | · | · | 29,344,993 | 15,784,750 | 319,202 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterest
us-gaap:InvestmentIncomeNonoperatingInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted